Legal & General Group Plc Makes New Investment in Urogen Pharma $URGN

Posted by Stanley Muller on Sep 7th, 2026

Legal & General Group Plc purchased a new stake in Urogen Pharma (NASDAQ:URGN – Free Report) during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 35,830 shares of the company’s stock, valued at approximately $1,319,000.

Several other institutional investors and hedge funds also recently made changes to their positions in the stock. AQR Capital Management LLC increased its position in shares of Urogen Pharma by 347.5% during the first quarter. AQR Capital Management LLC now owns 114,066 shares of the company’s stock worth $1,262,000 after acquiring an additional 88,577 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in shares of Urogen Pharma by 7.6% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 23,320 shares of the company’s stock worth $258,000 after acquiring an additional 1,653 shares during the period. Jane Street Group LLC lifted its position in Urogen Pharma by 94.3% in the 1st quarter. Jane Street Group LLC now owns 51,177 shares of the company’s stock valued at $566,000 after acquiring an additional 24,839 shares in the last quarter. Cetera Investment Advisers bought a new stake in Urogen Pharma in the 2nd quarter valued at $361,000. Finally, JPMorgan Chase & Co. boosted its stake in Urogen Pharma by 5.2% in the 2nd quarter. JPMorgan Chase & Co. now owns 390,364 shares of the company’s stock worth $5,348,000 after purchasing an additional 19,405 shares during the period. Institutional investors and hedge funds own 91.29% of the company’s stock.

Insider Activity at Urogen Pharma

In other news, insider Mark Schoenberg sold 60,677 shares of the stock in a transaction dated Thursday, August 20th. The shares were sold at an average price of $47.05, for a total transaction of $2,854,852.85. Following the completion of the transaction, the insider directly owned 59,086 shares in the company, valued at $2,779,996.30. This represents a 50.66% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. In the last three months, insiders have sold 80,677 shares of company stock worth $3,604,953. Corporate insiders own 4.80% of the company’s stock.

Analysts Set New Price Targets

A number of research firms have issued reports on URGN. Oppenheimer increased their target price on Urogen Pharma from $40.00 to $50.00 and gave the stock an “outperform” rating in a report on Thursday, July 16th. HC Wainwright boosted their price target on Urogen Pharma from $45.00 to $75.00 and gave the company a “buy” rating in a report on Thursday, August 6th. LADENBURG THALM/SH SH assumed coverage on Urogen Pharma in a research report on Monday, May 11th. They set a “buy” rating and a $43.00 price objective for the company. TD Cowen increased their price objective on Urogen Pharma from $50.00 to $60.00 and gave the stock a “buy” rating in a report on Wednesday, August 5th. Finally, Guggenheim lifted their target price on Urogen Pharma from $42.00 to $58.00 and gave the company a “buy” rating in a research report on Thursday, August 6th. One analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $50.38.

Get Our Latest Analysis on Urogen Pharma

Urogen Pharma Stock Performance

Shares of URGN opened at $44.09 on Monday. Urogen Pharma has a 12 month low of $15.86 and a 12 month high of $50.81. The firm has a fifty day simple moving average of $42.72 and a 200 day simple moving average of $30.83. The stock has a market capitalization of $2.16 billion, a price-to-earnings ratio of -22.27 and a beta of 1.57.

Urogen Pharma (NASDAQ:URGN – Get Free Report) last released its earnings results on Wednesday, August 5th. The company reported ($0.28) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.26) by ($0.02). The company had revenue of $72.46 million for the quarter, compared to analyst estimates of $63.55 million. As a group, research analysts predict that Urogen Pharma will post -0.2 earnings per share for the current fiscal year.

Urogen Pharma Profile

(Free Report)

UroGen Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for uro-oncology and uro-genital diseases. Founded in 2010 and headquartered in Ra’anana, Israel, with offices in New York, UroGen applies its proprietary RTGel® reverse thermal gel delivery platform to create sustained-release formulations designed for in-office use by urologists.

The company’s lead product, Jelmyto® (mitomycin gel), received U.S. Food and Drug Administration approval in 2020 for the treatment of adults with low-grade upper tract urothelial cancer.